Kuros Biosciences

Be on the lookout for our upcoming advertisement in the pre-NASS issue of Orthopedics This Week Magazine (OTW)! Our ad highlights a Level 1 investigator-initiated clinical study now published in 𝙎𝙥𝙞𝙣𝙚, where MagnetOsᵀᴹ was used standalone demonstrating a 79% fusion rate compared to 47% for autograft in PLF.¹ As a leader in musculoskeletal biologics, we are proud to support and engage with the vibrant community of orthopedic professionals who are shaping the future of patient care and innovation. A huge thank you to Orthopedics This Week for the opportunity to connect with such a dedicated audience. To learn more about this Level 1 clinical study, click here → https://lnkd.in/eWapu_mt #MagnetOs #KurosBiosciences #Level1Data #OTW #GrowBoneMagnetOs

We’re excited to share that our Scientific Affairs Manager, Luuk van Dijk, PhD, was given the opportunity to present at the 𝟮𝟰𝘁𝗵 𝗦𝘄𝗶𝘀𝘀 𝗦𝗼𝗰𝗶𝗲𝘁𝘆 𝗼𝗳 𝗦𝗽𝗶𝗻𝗮𝗹 𝗦𝘂𝗿𝗴𝗲𝗿𝘆 (𝗦𝗚𝗦) 𝗔𝗻𝗻𝘂𝗮𝗹 𝗠𝗲𝗲𝘁𝗶𝗻𝗴 in Basel. Luuk delivered two insightful presentations and was even honored with the "𝗕𝗲𝘀𝘁 𝗣𝗼𝘀𝘁𝗲𝗿 𝗣𝗿𝗲𝘀𝗲𝗻𝘁𝗮𝘁𝗶𝗼𝗻" 𝗮𝘄𝗮𝗿𝗱! 𝟭. 𝗣𝗼𝘀𝘁𝗲𝗿 𝗣𝗿𝗲𝘀𝗲𝗻𝘁𝗮𝘁𝗶𝗼𝗻: Luuk presented a retrospective clinical study on the use of MagnetOsᵀᴹ in interbody spinal fusion in a population with multiple comorbidities, and we’re delighted that his poster won the Best Poster Presentation award. Congratulations, Luuk!   𝟮. 𝗣𝗮𝗽𝗲𝗿 𝗣𝗿𝗲𝘀𝗲𝗻𝘁𝗮𝘁𝗶𝗼𝗻: Luuk also shared the findings from a prospective, randomized, controlled trial of posterolateral fusion, in which MagnetOs was found to be non-inferior and even indicated superiority to autograft in terms of radiographic fusion rate (79% vs 47% fusion rate).   We extend our sincere thanks to SGS for hosting an engaging event and for supporting the advancement of research in this field. We are looking forward to continued collaboration and progress in pushing the boundaries of innovation! #MagnetOs #SGS #KurosBiosciences #Level1Data

A company dedicated to advancing in the musculoskeletal biologics market! Learn about recent publication of Level 1 human clinical data in the esteemed 𝙎𝙥𝙞𝙣𝙚 journal. Ortho Summit Kuros Biosciences

We're thrilled to announce that Kuros Biosciences will be sponsoring both a faculty dinner and an investor booth at the upcoming 𝗢𝗦𝗘𝗧 𝗦𝘂𝗺𝗺𝗶𝘁 𝗛𝗲𝗮𝗹𝘁𝗵𝗽𝗼𝗶𝗻𝘁 𝗖𝗮𝗽𝗶𝘁𝗮𝗹 𝗜𝗻𝘃𝗲𝘀𝘁𝗼𝗿 event in 𝗟𝗮𝘀 𝗩𝗲𝗴𝗮𝘀, 𝗡𝗩 𝗼𝗻 𝗦𝗲𝗽𝘁𝗲𝗺𝗯𝗲𝗿 𝟭𝟯𝘁𝗵. As a company dedicated to advancing in the musculoskeletal biologics market, we're proud to showcase our commitment to data-driven innovation. Our recent publication of Level 1 human clinical data in the esteemed 𝙎𝙥𝙞𝙣𝙚 journal underscores our dedication to rigorous research and cutting-edge technology. We look forward to connecting with industry leaders and visionaries in Las Vegas! #OSETSummit #KurosBiosciences

Great day with Kuros Biosciences 🚀 in London, meeting institutional investors. Many thanks to Chris Fair and Daniel Geiger!

Will you be attending this year's SMISS annual forum in Las Vegas, NV? Visit the 𝗞𝘂𝗿𝗼𝘀 𝗯𝗼𝗼𝘁𝗵 #𝟮𝟭𝟭 where you can explore the recent Level 1 human clinical data featuring MagnetOsᵀᴹ 𝗻𝗼𝘄 𝗽𝘂𝗯𝗹𝗶𝘀𝗵𝗲𝗱 𝗶𝗻 𝙎𝙥𝙞𝙣𝙚 and discover our innovative NeedleGripᵀᴹ surface technology. #SMISS #MagnetOs #Level1Data #KurosBiosciences

Kuros Biosciences is pleased to report financial results for the first half of 2024 which have shown an extraordinary 𝗶𝗻𝗰𝗿𝗲𝗮𝘀𝗲 𝗼𝗳 𝟭𝟱𝟵% 𝗶𝗻 𝗱𝗶𝗿𝗲𝗰𝘁 𝗠𝗮𝗴𝗻𝗲𝘁𝗢𝘀ᵀᴹ 𝘀𝗮𝗹𝗲𝘀 from H1 2023.   Financial highlights also include significant increases in total Kuros medical device segment sales, EBITDA, cash and cash equivalents.   In addition to impressive financial highlights, 𝗞𝘂𝗿𝗼𝘀 𝗵𝗮𝗱 𝘀𝗲𝘃𝗲𝗿𝗮𝗹 𝗿𝗲𝗴𝘂𝗹𝗮𝘁𝗼𝗿𝘆, 𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹, 𝗮𝗻𝗱 𝗰𝗼𝗺𝗺𝗲𝗿𝗰𝗶𝗮𝗹 𝗮𝗰𝗵𝗶𝗲𝘃𝗲𝗺𝗲𝗻𝘁𝘀 𝗶𝗻 𝗛𝟭 𝟮𝟬𝟮𝟰 including Level 1 human clinical study outcomes published in Spine, new FDA clearances, and the launch of MagnetOs Granules and MagnetOs Putty in New Zealand.   Chris Fair, Chief Executive Officer of Kuros Biosciences, stated: “We are pleased to report first half 2024 results that continue to demonstrate our strong execution and commercialization, with direct MagnetOs revenue growth of 159% fueling the MagnetOs EBITDA margin of 27% and total Kuros Group EBITDA margin of 2%, adjusted at 12.5%. Our growing body of clinical evidence, including our recently published MAXA Level 1 clinical study in the peer-reviewed journal Spine, demonstrates how our differentiated technology continues to surpass expectations in providing compared to autograft a superior bone healing solution to surgeons and patients. With additional clearances from the FDA and other regulatory bodies currently applied for, we look forward to driving steady penetration of MagnetOs in the musculoskeletal biologics market.”   To read the full press release, click here → https://lnkd.in/eynjsYTm

OK, 𝙘𝙖𝙧𝙙𝙨 𝙤𝙣 𝙩𝙝𝙚 𝙩𝙖𝙗𝙡𝙚… There’s a lot we could say about the four MagnetOs™ bone grafts now FDA-cleared for interbody procedures. * But sometimes it’s best to just let the surgeon’s hands do the talking. Watch this one-minute POV video of a PLF and TLIF being performed with MagnetOs Flex Matrix → https://lnkd.in/edd-VBBV

It makes sense that you want to be holding 𝙖𝙡𝙡 𝙩𝙝𝙚 𝙘𝙖𝙧𝙙𝙨 when choosing a bone graft for interbody procedures. * So, what exactly can our MagnetOs™ product family help you achieve now that 𝗮𝗹𝗹 𝗳𝗼𝘂𝗿 𝗽𝗿𝗼𝗱𝘂𝗰𝘁𝘀 𝗮𝗿𝗲 𝗙𝗗𝗔-𝗰𝗹𝗲𝗮𝗿𝗲𝗱 𝗳𝗼𝗿 𝗶𝗻𝘁𝗲𝗿𝗯𝗼𝗱𝘆 𝘂𝘀𝗲? * • If you want a ready-to-use, easy-to-mold product that’s designed to stay put, and available for standalone use, try 𝗠𝗮𝗴𝗻𝗲𝘁𝗢𝘀 𝗘𝗮𝘀𝘆𝗽𝗮𝗰𝗸 𝗣𝘂𝘁𝘁𝘆. ¹˒² • For a bone graft that stays strong yet flexible even when hydrated with BMA, look no further than 𝗠𝗮𝗴𝗻𝗲𝘁𝗢𝘀 𝗙𝗹𝗲𝘅 𝗠𝗮𝘁𝗿𝗶𝘅. ³ • If you prefer a standalone bone graft for performing interbody procedures, we offer 𝗠𝗮𝗴𝗻𝗲𝘁𝗢𝘀 𝗣𝘂𝘁𝘁𝘆. ⁴ • Or you can use 𝗠𝗮𝗴𝗻𝗲𝘁𝗢𝘀 𝗚𝗿𝗮𝗻𝘂𝗹𝗲𝘀 in interbody procedures when hydrated with blood. ⁵ If you want to know which MagnetOs product best meets the unique needs of you and your patient, schedule a Meet the Expert session today → https://lnkd.in/eZpMrvqB

How are we 𝗿𝗮𝗶𝘀𝗶𝗻𝗴 𝘁𝗵𝗲 𝘀𝘁𝗮𝗸𝗲𝘀 in spinal fusion technology? In addition to the FDA having cleared all four MagnetOs™ bone grafts for use in the interbody space*, we continue to value research from leading surgeons demonstrating their experiences with MagnetOs in interbody procedures. In a retrospective clinical study, 𝗠𝗮𝗴𝗻𝗲𝘁𝗢𝘀 𝗮𝗰𝗵𝗶𝗲𝘃𝗲𝗱 𝟵𝟰.𝟮% 𝗳𝘂𝘀𝗶𝗼𝗻 𝗶𝗻 𝗹𝘂𝗺𝗯𝗮𝗿 𝗶𝗻𝘁𝗲𝗿𝗯𝗼𝗱𝘆 𝗰𝗮𝘀𝗲𝘀 (49 of 52 patients). ¹ To read the retrospective clinical study, click here → https://lnkd.in/ekudkN3x